The FDA has issued a safety alert concerning specific CooperSurgical INCA Infant Nasal CPAP devices. This early alert focuses on a potentially hazardous issue—a loose connection between the flexible tubing and the nasal cannula. This flaw could result in a failure to maintain continuous positive airway pressure (CPAP), potentially leading to reduced oxygenation.
# Affected Devices
According to the FDA, the units affected are from certain lots of both the INCA Infant Nasal CPAP Complete Set and Replacement Set. Each affected product is identified with specific part numbers and lot codes which should be reviewed by users to determine if their devices are involved.
# Recommended Actions
- Cease Use: Immediately stop using the affected devices.
- Segregate and Return: Separate these devices from active inventory and return them to CooperSurgical.
- Inform Personnel: Notify all facility staff about the issue.
- Contact Other Facilities: If the products have been distributed to other facilities, ensure they are informed.
- Check for Updates: Regularly review the FDA web page for the latest information.
# Risk and Response
The primary risk associated with this defect is the potential for decreased oxygenation due to loss of CPAP pressure. Although no severe injuries or fatalities have been reported so far, the risk of compromised respiratory support necessitated the alert.
# Conclusion
The alert underscores the importance of adherence to medical device notifications for patient safety. Users should follow FDA guidelines and CooperSurgical directions to prevent potential adverse effects.
For further information, users may contact the CooperSurgical Recall Support Team or refer to the FDA MedWatch Safety Alerts.